Notably, patients with essential thrombocythemia, particularly those carrying the JAK2 V617F mutation, may have an increased risk of HIT-associated thrombosis, highlighting the potential synergistic effect of essential thrombocythemia and HIT in promoting extensive thrombotic complications [13]. Here, JAK2 is linked to essential thrombocythemia.